<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218451</url>
  </required_header>
  <id_info>
    <org_study_id>670901</org_study_id>
    <nct_id>NCT01218451</nct_id>
  </id_info>
  <brief_title>NeisVac-C Single Prime Study in Infants</brief_title>
  <official_title>A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility of a single priming dose of NeisVac-C
      in infants (at either 4 or 6 months of age), as determined by immune response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with seroprotective antibody titers (rSBA titers &gt;= 8) 1 month after completion of the primary vaccination in single-dose groups compared to the two-dose group</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with seroprotective antibody titers (rSBA titers &gt;= 8) prior to the administration of the booster dose</measure>
    <time_frame>6 to 9 months (from 4-6 months of age until 12-13 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with seroprotective antibody titers (rSBA titers &gt;= 128) 1 month after the administration of the booster dose</measure>
    <time_frame>1 month after booster dose (administered between 12-13 months of age)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody titers (rSBA) titers one month after completion of the primary vaccination</measure>
    <time_frame>1 month after primary vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers (rSBA titers) prior to the administration of the booster dose</measure>
    <time_frame>Prior to booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers (rSBA titers)one month after the administration of the booster dose</measure>
    <time_frame>1 month after administration of booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of local and systemic ractions with onset within 3 days after each vaccination</measure>
    <time_frame>Within 3 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events observed during the entire follow up period</measure>
    <time_frame>Entire follow up period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">956</enrollment>
  <condition>Neisseria Meningitidis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of NeisVac-C vaccine at 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of NeisVac-C vaccine at 6 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two doses of NeisVac-C vaccine at 2 and 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal group C polysaccharide conjugate vaccine</intervention_name>
    <description>0.5 mL dose, subcutaneous administration in right anterolateral thigh</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>NeisVac-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal 13-valent conjugate vaccine</intervention_name>
    <description>0.5 mL dose, subcutaneous administration in right anterolateral thigh</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Prevenar 13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine</intervention_name>
    <description>0.5 mL dose, subcutaneous administration in right anterolateral thigh</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Infanrix hexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is an infant aged 8 to 11 weeks at the time of first vaccination

          -  Subject is clinically healthy as determined by the investigator's clinical judgment
             through collection of medical history and physical examination

          -  Subject was born at full term of pregnancy (&gt;= 37 weeks) with a birth weight &gt;= 2 kg

          -  The parent(s) or legally authorized representative of the subject provides written
             consent for participation

          -  The parent(s) or legally authorized representative of the subject has the ability to
             understand and comply with the requirements of the protocol

          -  The parent(s) or legally authorized representative and the subject will be available
             for the duration of the study

          -  The parent(s) or legally authorized representative of the subject agrees to keep a
             subject diary

        Exclusion Criteria:

          -  Subject has a history of severe allergic reactions or anaphylaxis, or has a known
             sensitivity or allergy to any components of the vaccines

          -  Subject has had an acute or chronic infection requiring systemic therapy (antibiotic
             or antiviral) or other prescribed treatment within the 2 weeks prior to the first
             vaccination in this study

          -  Subject has a rash or dermatologic condition which may interfere with injection site
             reaction rating

          -  Subject currently has, or has a history of, any significant cardiovascular,
             respiratory, hepatic, renal, metabolic, autoimmune, rheumatic, hematological,
             neurological, or neurodevelopmental disorder

          -  Subject has a disease, or is currently undergoing a form of treatment, or was
             undergoing a form of treatment within 30 days prior to study entry, that could be
             expected to influence immune response

          -  Subject has received any blood products or immunoglobulins within 60 days of study
             entry

          -  Subject has received a live vaccine within 4 weeks or an inactivated or subunit
             vaccine within 2 weeks of the scheduled first vaccination

          -  Subject has previously been vaccinated against meningococcal C disease

          -  Subject has a known or suspected immune dysfunction

          -  Subject has a functional or surgical asplenia (e.g. due to a pathologic
             hemoglobinopathy, leukemia, lymphoma, etc.)

          -  Subject was administered an investigational drug within six weeks prior to study entry
             or is concurrently participating in a clinical study that includes the administration
             of an investigational product

          -  Subject or his/her parent(s) / legally authorized representative are in a dependent
             relationship with the study investigator or with a study team member; dependent
             relationships include close relatives (i.e. children, partner/spouse, siblings) as
             well as employees of the investigator or site conducting the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Weeks</minimum_age>
    <maximum_age>11 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baxter BioScience Investigator, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NZOZ Vitamed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Specjalistyczny Szpital Dziecięcy im. Sw. Ludwika w Krakowie, Poradnia Pediatryczna Szczepien dla Dzieci z Grup Wysokiego Ryzyka</name>
      <address>
        <city>Krakow</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im. W. Bieganskiego, Oddzial Obserwacyjno-Zakazny dla Dzieci</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Oddział Pediatyczny</name>
      <address>
        <city>Lubartow</city>
        <zip>21-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia Medycyny Wieku Rozwojowego</name>
      <address>
        <city>Poznan</city>
        <zip>61-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZLA Michałkowice Jarosz i partnerzy spolka lekarska</name>
      <address>
        <city>Siemianowice</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z o.o.</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital im. Świętej Jadwigi Śląskiej, Oddział Dziecięcy</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPSK nr 1 we Wrocławiu, Klinika Pediatrii i Chorób Infekcyjnych</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-345</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Zawidawie - Centrum Medyczne &quot;Zatorska&quot;</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-315</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>Almassora</city>
        <zip>12550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>Castellón de la Plana</city>
        <zip>12006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>Catarroja</city>
        <zip>46470</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>L´Eliana</city>
        <zip>46183</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>Puçol</city>
        <zip>46530</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>Quart de Poblet</city>
        <zip>46930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>Sagunto</city>
        <zip>46500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Hispalense de Pediatria</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial Universitario Joan XXIII de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>Valencia</city>
        <zip>46013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>Valencia</city>
        <zip>46021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSISP. Centro Superior de Investigación en Salud Pública</name>
      <address>
        <city>Valencia</city>
        <zip>46024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal Axarquía</name>
      <address>
        <city>Vélez-Málaga</city>
        <zip>29700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

